Astellas Pharma

Brief quote from Bob Lanza on Ocata acquisition by Astellas

Robert-Lanza

I asked Ocata CSO, Bob Lanza, for a comment on the big news of the acquisition of the company by Astellas. Here’s what he had to say: “I can say that this is an exciting time for regenerative medicine.  The merger should greatly accelerate the pace of discovery, and, I hope, lead to treatments for …

Brief quote from Bob Lanza on Ocata acquisition by Astellas Read More »

Ocata bought by Astellas of Japan: initial perspectives on end of an era

Astellas

Bombshell news in the stem cell field as Ocata Therapeutics (OCAT; formerly Advanced Cell Technology or ACT) is reportedly to be acquired by Astellas Pharma, Inc. The offer for purchase of OCAT will be $8.50/share or almost $380 million. For more details see this detailed PDF from Astellas. This quote on the deal form Ocata: “Paul …

Ocata bought by Astellas of Japan: initial perspectives on end of an era Read More »